A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease

Journal of Neurology

Volumn 263, Issue 7, 2016, Pages 1390-1400

  López Sendón Moreno, Jose Luis ^a,e,f   García Caldentey, Juan ^a   Trigo Cubillo, Patricia ^a   Ruiz Romero, Carolina ^a   García Ribas, Guillermo ^a   Alonso Arias, M A Alonso ^a   García de Yébenes, María Jesús ^b   Tolón, Rosa María ^c   Galve Roperh, Ismael ^d,e,f   Sagredo, Onintza ^d,e,f   Valdeolivas, Sara ^d,e,f   Resel, Eva ^d,e,f   Ortega Gutierrez, Silvia ^d   García Bermejo, María Laura ^f   Fernández Ruiz, Javier ^d,e,f   Guzmán, Manuel ^d,e,f   García de Yébenes Prous, Justo ^a,e  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b Instituto de Salud Musculoesquelética InMusc Calle Hilarión Eslava   (Spain)

^c HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^e CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^f INSTITUTO RAMÓN Y CAJAL DE INVESTIGACIÓN SANITARIA IRYCIS   (Spain)

Author keywords

Cannabinoid; Clinical trial; Huntington s disease; Sativex

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; ENDOCANNABINOID; MICRORNA; MICRORNA 34B; MONOAMINE; NABIXIMOLS; PLACEBO; UNCLASSIFIED DRUG; AMINO ACID; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); BIOGENIC AMINE; MIRN34 MICRORNA, HUMAN; PEPTIDE FRAGMENT; PLANT EXTRACT; TAU PROTEIN; TETRAHYDROCANNABINOL-CANNABIDIOL COMBINATION;

ADULT; ANXIETY; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; GENE EXPRESSION; HEADACHE; HUMAN; HUNTINGTON CHOREA; INFECTION; INSOMNIA; MALE; MYALGIA; PERIPHERAL LYMPHOCYTE; PILOT STUDY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RANDOMIZED CONTROLLED TRIAL; SKIN FIBROBLAST; SOMNOLENCE; UNIFIED HUNTINGTON DISEASE RATING SCALE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; BLOOD; CEREBROSPINAL FLUID; DRUG EFFECTS; FIBROBLAST; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; HUNTINGTON DISEASE; MENTAL HEALTH; METABOLISM; MIDDLE AGED; OUTCOME ASSESSMENT; PLANT STRUCTURES; SEVERITY OF ILLNESS INDEX;

ADULT; AMINO ACIDS; AMYLOID BETA-PEPTIDES; BIOGENIC MONOAMINES; CROSS-OVER STUDIES; ENDOCANNABINOIDS; FEMALE; FIBROBLASTS; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION; HUMANS; HUNTINGTON DISEASE; MALE; MENTAL STATUS SCHEDULE; MICRORNAS; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PEPTIDE FRAGMENTS; PILOT PROJECTS; PLANT EXTRACTS; PLANT STRUCTURES; SEVERITY OF ILLNESS INDEX; TAU PROTEINS;

EID: 84966474733     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-016-8145-9     Document Type: Article

References (49)

1. Walker FO (2007) Huntington’s disease. Lancet 369(9557):218–228
2. The Huntington’s Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72(6):971–983
3. Rosas HD, Salat DH, Lee SY et al (2008) Cerebral cortex and the clinical expression of Huntington’s disease: complexity and heterogeneity. Brain 131(Pt 4):1057–1068
4. Marsicano G, Goodenough S, Monory K et al (2003) CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302(5642):84–88
5. Cota D (2007) CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes Metab Res Rev 23(7):507–517
6. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M (2009) Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89(1):309–380
7. Wright S (2007) Cannabinoid-based medicines for neurological disorders–clinical evidence. Mol Neurobiol 36(1):129–136
8. Fernandez-Ruiz J (2009) The endocannabinoid system as a target for the treatment of motor dysfunction. Br J Pharmacol 156(7):1029–1040
9. Pazos MR, Sagredo O, Fernandez-Ruiz J (2008) The endocannabinoid system in Huntington’s disease. Curr Pharm Des 14(23):2317–2325
10. Fernandez-Ruiz J, Romero J, Velasco G, Tolon RM, Ramos JA, Guzman M (2007) Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends Pharmacol Sci 28(1):39–45
11. Fernandez-Ruiz J, Garcia C, Sagredo O, Gomez-Ruiz M, de Lago E (2010) The endocannabinoid system as a target for the treatment of neuronal damage. Expert Opin Ther Targets 14(4):387–404
12. Pertwee RG (2009) Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 156(3):397–411
13. Gowran A, Noonan J, Campbell VA (2011) The multiplicity of action of cannabinoids: implications for treating neurodegeneration. CNS Neurosci Ther 17(6):637–644
14. Kluger B, Triolo P, Jones W, Jankovic J (2015) The therapeutic potential of cannabinoids for movement disorders. Mov Disord 30(3):313–327
15. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11(2):563–583
16. Nunez E, Benito C, Tolon RM, Hillard CJ, Griffin WS, Romero J (2008) Glial expression of cannabinoid CB(2) receptors and fatty acid amide hydrolase are beta amyloid-linked events in Down’s syndrome. Neuroscience 151(1):104–110
17. Toth A, Blumberg PM, Boczan J (2009) Anandamide and the vanilloid receptor (TRPV1). Vitam Horm 81:389–419
18. van der Stelt M, Veldhuis WB, Maccarrone M et al (2002) Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol Neurobiol 26(2–3):317–346
19. Chiarlone A, Bellocchio L, Blazquez C et al (2014) A restricted population of CB1 cannabinoid receptors with neuroprotective activity. Proc Natl Acad Sci USA 111(22):8257–8262
20. Palazuelos J, Aguado T, Pazos MR et al (2009) Microglial CB2 cannabinoid receptors are neuroprotective in Huntington’s disease excitotoxicity. Brain 132(Pt 11):3152–3164
21. Hampson AJ, Grimaldi M, Axelrod J, Wink D (1998) Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 95(14):8268–8273
22. Muller-Vahl KR, Schneider U, Emrich HM (1999) Nabilone increases choreatic movements in Huntington’s disease. Mov Disord 14(6):1038–1040
23. Curtis A, Rickards H (2006) Nabilone could treat chorea and irritability in Huntington’s disease. J Neuropsychiatry Clin Neurosci 18(4):553–554
24. Curtis A, Mitchell I, Patel S, Ives N, Rickards H (2009) A pilot study using nabilone for symptomatic treatment in Huntington’s disease. Mov Disord 24(15):2254–2259
25. Consroe P, Laguna J, Allender J et al (1991) Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacol Biochem Behav 40(3):701–708
26. Russo E, Guy GW (2006) A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 66(2):234–246
27. Lastres-Becker I, Bizat N, Boyer F, Hantraye P, Fernandez-Ruiz J, Brouillet E (2004) Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo. NeuroReport 15(15):2375–2379
28. Sagredo O, Ramos JA, Decio A, Mechoulam R, Fernandez-Ruiz J (2007) Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. Eur J Neurosci 26(4):843–851
29. Valdeolivas S, Satta V, Pertwee RG, Fernandez-Ruiz J, Sagredo O (2011) Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington’s disease: role of CB1 and CB2 receptors. ACS Chem Neurosci 3(5):400–406
30. Huntington Study Group (1996) Unified Huntington’s Disease Rating Scale: reliability and consistency. Mov Disord 11(2):136–142
31. Gomez-Tortosa E, Gonzalo I, Fanjul S et al (2003) Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease. Arch Neurol 60(9):1218–1222
32. Reiriz J, Mena MA, Bazan E et al (1989) Temporal profile of levels of monoamines and their metabolites in striata of rats implanted with dialysis tubes. J Neurochem 53(3):789–792
33. Gaughwin PM, Ciesla M, Lahiri N, Tabrizi SJ, Brundin P, Bjorkqvist M (2011) Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington’s disease. Hum Mol Genet 20(11):2225–2237
34. Hernandez-Torres G, Cipriano M, Heden E et al (2014) A reversible and selective inhibitor of monoacylglycerol lipase ameliorates multiple sclerosis. Angew Chem Int Ed Engl 53(50):13765–13770
35. Bisogno T, Martire A, Petrosino S, Popoli P, Di Marzo V (2008) Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington’s disease. Neurochem Int 52(1–2):307–313
36. Fernandez-Estevez MA, Casarejos MJ, Lopez Sendon J et al (2014) Trehalose reverses cell malfunction in fibroblasts from normal and Huntington’s disease patients caused by proteosome inhibition. PLoS One 9(2):e90202
37. Battista N, Bari M, Tarditi A et al (2007) Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington’s disease mutation in peripheral lymphocytes. Neurobiol Dis 27(1):108–116
38. Casarejos MJ, Perucho J, Gomez A et al (2013) Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy. J Alzheimers Dis 35(3):525–539
39. Tapiola T, Alafuzoff I, Herukka SK et al (2009) Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66(3):382–389
40. Giampa C, Montagna E, Dato C, Melone MA, Bernardi G, Fusco FR (2013) Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington’s disease. PLoS One 8(5):e64037
41. Zuccato C, Ciammola A, Rigamonti D et al (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington’s disease. Science 293(5529):493–498
42. Chang KH, Chen YC, Wu YR, Lee WF, Chen CM (2012) Downregulation of genes involved in metabolism and oxidative stress in the peripheral leukocytes of Huntington’s disease patients. PLoS One 7(9):e46492
43. Sagredo O, Gonzalez S, Aroyo I et al (2009) Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington’s disease. Glia 57(11):1154–1167
44. Butovsky E, Juknat A, Goncharov I et al (2005) In vivo up-regulation of brain-derived neurotrophic factor in specific brain areas by chronic exposure to Delta-tetrahydrocannabinol. J Neurochem 93(4):802–811
45. D’Souza DC, Pittman B, Perry E, Simen A (2009) Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans. Psychopharmacology 202(4):569–578
46. De Petrocellis L, Ligresti A, Moriello AS et al (2011) Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 163(7):1479–1494
47. Thieme D, Sachs H, Uhl M (2014) Proof of cannabis administration by sensitive detection of 11-nor-Delta(9)-tetrahydrocannabinol-9-carboxylic acid in hair using selective methylation and application of liquid chromatography- tandem and multistage mass spectrometry. Drug Test Anal 6(1–2):112–118
48. Blazquez C, Chiarlone A, Sagredo O et al (2011) Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington’s disease. Brain 134(Pt 1):119–136
49. Van Laere K, Casteels C, Dhollander I et al (2010) Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo. J Nucl Med 51(9):1413–1417